Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)

By Pritchard Kathleen  

Breast Cancer Research and Treatment, Vol. 123, Iss. 2, 2010-09 ,pp. : 453-461

Springer Publishing Company

Access to resources Recommend Favorite

Prolonged time to progression with fulvestrant for metastatic breast cancer

By Mello Celso  

Medical Oncology, Vol. 28, Iss. 2, 2011-06 ,pp. : 416-419

Humana Press, Inc

Access to resources Recommend Favorite

Fulvestrant (Faslodex&unknown;) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

By Mauriac L.   Pippen J.E.   Quaresma Albano J.   Gertler S.Z.   Osborne C.K.  

European Journal of Cancer, Vol. 39, Iss. 9, 2003-06 ,pp. : 1228-1233

Elsevier

Access to resources Recommend Favorite

Fulvestrant versus anastrazole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials

By  

The Women's Oncology Review, Vol. 4, Iss. 2, 2004-06 ,pp. : 137-138

Informa Healthcare

Access to resources Recommend Favorite

A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer

By Massarweh Suleiman  

Breast Cancer Research and Treatment, Vol. 129, Iss. 3, 2011-10 ,pp. : 819-827

Springer Publishing Company

Access to resources Recommend Favorite